Rethinking ESR1 Testing in HR+/HER2– Advanced Breast Cancer

Description:

Discover how recent Phase 3 trials in HR+/HER2– advanced breast cancer are exploring a potential shift from the current ESR1 testing strategy to an investigational approach.^1-3 This video explains the role of ESR1 mutations in breast cancer progression,⁴ how they contribute to endocrine resistance,⁴ and how early detection through circulating tumor DNA (ctDNA) monitoring may help identify patients at risk of disease progression sooner.^1,2

This program discusses:

• The clinical implications of ESR1 mutations in HR+/HER2– advanced breast cancer

• Limitations of current ESR1 testing strategies and rationale for investigational approaches

• How an investigational strategy may help detect emerging endocrine resistance before clinical progression

References:

1. Bidard FC, Hardy-Bessard AC, Dalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367-1377.
2. Turner N, Huang-Bartlett C, Kalinsky K, et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023;19(8):559-573.
3. Burstein HJ, DeMichele A, Somerfield MR, Henry NL; Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline rapid recommendation update. J Clin Oncol. 2023;41(18):3423-3425.
4. Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85.

Target Audience: Early Career Professionals, Mid- to Late-Career Professionals, Molecular Technologists, Managers/Quality Assurance/Supervisors, Analysts/Bioinformaticians, and Non-pathologists.

Duration: 3 minutes

CME/CMLE is NOT available for this educational activity.

Enroll